The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail

Zerseos 0.5 mg/2.5 mg per 2.5 ml nebuliser solution

Azure Pharmaceuticals LtdPA22871/011/001

Main Information

Trade NameZerseos 0.5 mg/2.5 mg per 2.5 ml nebuliser solution
Active SubstancesIpratropium bromide monohydrate
Dosage FormNebuliser solution
Licence HolderAzure Pharmaceuticals Ltd
Licence NumberPA22871/011/001

Group Information

ATC CodeR03AK Adrenergics in combination with corticosteroids or other drugs, excl. anticholinergics
R03AK04 salbutamol and sodium cromoglicate


License statusAuthorised
Licence Issued10/03/2017
Legal statusProduct subject to prescription which may be renewed (B)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusNot marketed


Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available

Generics Information

Interchangeable List CodeIC0081-136-052
Interchangeable List DocumentPDF of Interchangeable List
« Back